GFlowNets for Drug Discovery: Interpretability Study Reveals Limits
A recent preprint on arXiv (2511.19264) details an interpretability study of SynFlowNet, a synthesis-aware Generative Flow Network (GFlowNet) that utilizes a drug-likeness (QED) reward. Conducted by a team of researchers, the study tackles the challenges posed by the opaque internal policies of GFlowNet, which hinder its use in drug discovery, where chemists seek understandable justifications for suggested molecular designs. The research employs a combination of gradient saliency, counterfactual edits, undercomplete factor analysis, and an overcomplete BatchTopK sparse autoencoder. Evaluations include shuffled-label controls and RDKit-descriptor baselines. Notably, findings reveal that the embeddings from SynFlowNet are more indicative of general molecular features than specific synthesis knowledge. This study was marked as a replace-cross on arXiv, signaling a revision, and adds to the expanding area of interpretable AI in scientific research, especially in drug discovery.
Key facts
- Preprint arXiv:2511.19264v2
- Announce type: replace-cross
- Study focuses on SynFlowNet, a synthesis-aware GFlowNet
- Trained with drug-likeness (QED) reward
- Interpretability framework includes gradient saliency and counterfactual edits
- Uses undercomplete factor analysis and overcomplete BatchTopK sparse autoencoder
- Evaluated with shuffled-label controls, RDKit-descriptor baselines, scaffold-disjoint split, cross-seed stability, and architecture-matched untrained network
- Physicochemical properties and functional groups are highly decodable from embeddings
- Untrained network performs as well as trained policy
- Published on arXiv
Entities
Institutions
- arXiv